Gwendolyn K. Binder
President of Science & TechnologyDr. Gwendolyn K. Binder, also known as Gwen, Ph.D., had been an Executive Vice President of Science and Technology at Cabaletta Bio, Inc. since February 1, 2019 until January 2022 and has been its President of Science and Technology since January 2022. Dr. Binder joined the Cabaletta Bio, Inc. on February 01, 2019. She serves as Non-Employee Director of Instil Bio, Inc. since July 2020. Dr. Binder has been a Member of Scientific Advisory Board at Immatics N.V. since 2020. She leads product research as well as all aspects of manufacturing innovation and operations for Cabaletta. She joined Cabaletta on February 1, 2019. She has been Scientific Founder of TMune Therapeutics, Inc., since 2008. From March 2016 to January 31, 2019, she served as Chief Technology Officer of Adaptimmune Therapeutics plc, where she initially established and led capabilities in manufacturing, correlative science, compliance, regulatory and clinical operations, to enable the transfer of certain T cell receptor clinical programs from the Translational Research Program at the University of Pennsylvania, now known as the Center for Cellular Immunotherapy (CCI) and vector and cell manufacturing; and also Executive Vice President, Head of Translational Sciences from March 2011 to February 2016. She served as Head of Translational Sciences and Executive Vice-President at Adaptimmune Therapeutics plc from May 2015 to February 9, 2016 and served as an Executive Vice President of Adaptimmune LLC since 2012. She served as Vice President of Operations at Adaptimmune LLC since March 2011. She went on to lead Adaptimmune's approximately 150-person research team. Dr. Binder has industry and academic leadership in translational research and development, T cell manufacturing and the early development of first-in-human engineered T cell therapies. She served as a Director of Translational Research Operations at the University of Pennsylvania from 2006 to 2011 and Director of Scientific Affairs at Virxsys Corporation. Dr. Binder received her Ph.D. from the Johns Hopkins University School of Medicine in Cellular and Molecular Medicine in 2002, with a focus in viral immunology and her B.A. from Wells College.
Positions
- Company NameCabaletta Bio, Inc.Stock CodeCABAPositionPresident of Science & TechnologyColleagues
- SASteven A. NichtbergerCo-Founder, Chairman, CEO & President
- DJDavid J. ChangChief Medical Officer
- GKGwendolyn K. BinderPresident of Science & Technology
- MCMichael C. MiloneCo-Founder & Co-Chair of Scientific Advisory Board
- APAimee PayneCo-Founder & Co-Chair of Scientific Advisory Board
- RCRichard C. HenriquesIndependent Director
- SCScott C. BrunIndependent Director
- Company NameInstil Bio, Inc.Stock CodeTILPositionIndependent Non-Employee Director
